Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors in NSCLC. Recent experiences

N van Zandwijk1, W J Mooi, S Rodenhuis

  • 1Department of Chest Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Huis, Amsterdam.

Lung Cancer (Amsterdam, Netherlands)
|April 1, 1995
PubMed
Summary

New prognostic factors, including K-ras mutations and p53 abnormalities, offer insights into non-small cell lung cancer. Further studies are needed to determine their role in guiding patient treatment selection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a history-taking form for mesothelioma patients at risk of exposure to asbestos.

Public health action·2025
Same author

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

British journal of cancer·2018
Same author

[A brown-red papule].

Nederlands tijdschrift voor geneeskunde·2017
Same author

Incidence and relative survival of melanoma in children and adolescents in the Netherlands, 1989-2013.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

[Increasing incidence of thin melanomas in the Netherlands].

Nederlands tijdschrift voor geneeskunde·2017
Same author

PET/CT with <sup>18</sup>F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Non-small cell lung cancer (NSCLC) prognosis traditionally relies on clinical factors.
  • Emerging molecular and biological markers are enhancing prognostic assessments.
  • Understanding these new factors is crucial for advancing lung cancer care.

Purpose of the Study:

  • To highlight newly identified prognostic factors in non-small cell lung cancer.
  • To emphasize the clinical significance of these emerging biomarkers.
  • To advocate for prospective studies on these factors for treatment selection.

Main Methods:

  • Review of recent advancements in NSCLC prognostic factor identification.
  • Analysis of specific biomarkers: K-ras oncogene mutations, p53 abnormalities, N-CAM expression (Mab immunostaining), and serum neuron-specific enolase (NSE) levels.

Related Experiment Videos

  • Discussion of the clinical implications of these factors.

    • Main Results:

    • Identification of K-ras mutations, p53 abnormalities, N-CAM expression, and elevated NSE as significant prognostic factors.
    • These factors provide deeper insights into NSCLC biology.
    • Current evidence suggests potential utility in patient management.

    Conclusions:

    • New molecular and biological markers significantly contribute to NSCLC prognostication.
    • Prospective research is essential to validate the role of these biomarkers in treatment decisions.
    • Integrating these factors may lead to more personalized lung cancer therapies.